OXYMETAZOLINE

US Approved OTC

First approved in 1964

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H24N2O
Molecular Weight	260.3746
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(=C(O)C(C)=C1CC2=NCCN2)C(C)(C)C

InChI

InChIKey=WYWIFABBXFUGLM-UHFFFAOYSA-N

InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C16H24N2O
Molecular Weight	260.3746
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB00935
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/monograph/oxymetazoline-hydrochloride.html

Oxymetazoline is an adrenergic alpha-agonist, direct acting sympathomimetic, used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis. Oxymetazoline is self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies. Oxymetazoline is available over-the-counter as a topical decongestant in the form of oxymetazoline hydrochloride in nasal sprays such as Afrin, Operil, Dristan, Dimetapp, oxyspray, Facimin, Nasivin, Nostrilla, Sudafed OM, Vicks Sinex, Zicam, SinuFrin, and Mucinex Full Force. Due to its vasoconstricting properties, oxymetazoline is also used to treat nose bleeds and eye redness.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Adrenergic receptor alpha 64 Target ID: CHEMBL2095203 Sources: https://www.drugbank.ca/drugs/DB00935 \| https://www.ncbi.nlm.nih.gov/pubmed/20030735 \| https://www.ncbi.nlm.nih.gov/pubmed/11844675	Agonist 2662	4.96 null [pEC50]
Alpha-2a adrenergic receptor 61 Target ID: CHEMBL1867 Sources: https://www.drugbank.ca/drugs/DB00935 \| https://www.ncbi.nlm.nih.gov/pubmed/24365159 \| https://www.ncbi.nlm.nih.gov/pubmed/1974694	Partial Agonist 288	0.29 nM [Ki]
Serotonin 1a (5-HT1a) receptor 171 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678720	Agonist 2662	7.73 null [pEC50]
Serotonin 1d (5-HT1d) receptor 52 Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678720	Agonist 2662	7.35 null [pEC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Nasal congestion 26 Sources: https://www.drugs.com/ppa/oxymetazoline-nasal.html	Palliative		Approved 8360	Oxymetazoline Hydrochloride Approved Use Temporary relief of nasal congestion (due to a cold, hay fever, or other upper respiratory allergies) and sinus congestion/pressure. Launch Date 6.0721922E11
Eye irritations 2 Sources: https://www.drugs.com/cdi/oxymetazoline-drops.html	Primary		Approved 8360	OCUCLEAR Approved Use Relief of redness of eye due to minor eye irritations Launch Date 5.17795185E11

C_max

Value	Dose	Co-administered	Analyte	Population
60.5 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	20 mg single, topical dose: 20 mg route of administration: Topical experiment type: SINGLE co-administered:		OXYMETAZOLINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.78 ng/mL DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
895 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	20 mg single, topical dose: 20 mg route of administration: Topical experiment type: SINGLE co-administered:		OXYMETAZOLINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.24 ng × h/mL DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.23 h DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.05 % single, intranasal Dose: 0.05 % Route: intranasal Route: single Dose: 0.05 % Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	Other AEs: Hypertensive crisis... Other AEs: Hypertensive crisis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/23679077
1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	Disc. AE: Application site dermatitis, Application site erythema... AEs leading to discontinuation/dose reduction: Application site dermatitis (1.4%) Application site erythema (0.5%) Application site pain (0.5%) Application site dryness (0.2%) Hypoesthesia (0.2%) Paresthesia (0.2%) Rash (0.2%) Urticaria (0.2%) Photosensitivity reaction (0.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
1.5 % 2 times / day multiple, topical Highest studied dose Dose: 1.5 %, 2 times / day Route: topical Route: multiple Dose: 1.5 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29462230	unhealthy, adult Health Status: unhealthy Condition: Erythema Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/29462230	Sources: https://pubmed.ncbi.nlm.nih.gov/29462230

AEs

AE	Significance	Dose	Population
Hypertensive crisis	1 patient	0.05 % single, intranasal Dose: 0.05 % Route: intranasal Route: single Dose: 0.05 % Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23679077
Application site dryness	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Hypoesthesia	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Paresthesia	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Photosensitivity reaction	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Rash	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Urticaria	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site erythema	0.5% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site pain	0.5% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site dermatitis	1.4% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 768 substrate 1709	inhibitor 1752 substrate 1010	inhibitor 1837 substrate 1193	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2B6 799 CYP2C8 901 CYP2C19 1463 CYP3A4/5 273	CYP2C19 985 CYP1A2 1032 CYP2B6 660 CYP2C8 688 CYP2C18 139 CYP2E1 648 UGT1A9 380 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A8 283 UGT1A10 290 UGT2B4 249 UGT2B7 389 UGT2B15 203 UGT2B17 213	CYP1A2 689 CYP2B6 538

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1673	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2B6 985	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2B6 985	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C8 955	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP3A4 1909	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP3A4/5 330	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1032	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2B6 660	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C18 139	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C8 688	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C9 1010	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2D6 1193	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2E1 648	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP3A4 1709	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
UGT1A1 418	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A10 290	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A3 422	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A4 347	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A6 307	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A8 283	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B15 203	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B17 213	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B4 249	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B7 389	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A9 380	substrate 3326 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	yes
CYP2C19 985	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/; Page: 7.0	yes	no (co-administration study) Comment: concomitant oral moderate CYP2C19 inhibitors (e.g., esomeprazole, fluoxetine, and omeprazole): the results did not indicate an increase in oxymetazoline exposure associated with coadministration of oral moderate CYP2C19 inhibitors Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/; Page: 7.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208552Orig1s000PharmR.pdf#page=19 Page: 19.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7862	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7862
ChemicalBook	CB0371500	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0371500
ZINC	ZINC000000057435	http://zinc15.docking.org/substances/ZINC000000057435
eMolecules	902254	https://www.emolecules.com/cgi-bin/more?vid=902254

PubMed

Title	Date	PubMed
Differential capacities of the RGS1, RGS16 and RGS-GAIP regulators of G protein signaling to enhance alpha2A-adrenoreceptor agonist-stimulated GTPase activity of G(o1)alpha.	2001 Aug	11520900
The effect of inferior turbinate hypertrophy on nasal spray distribution to the middle meatus.	2001 Dec	11843929
Clonidine-induced nitric oxide-dependent vasorelaxation mediated by endothelial alpha(2)-adrenoceptor activation.	2001 Nov	11682443
Vasocontractile effects of alpha 2-adrenergic agonists associated with intracellular calcium release.	2002	12434541
The effects of topical agents of fluticasone propionate, oxymetazoline, and 3% and 0.9% sodium chloride solutions on mucociliary clearance in the therapy of acute bacterial rhinosinusitis in vivo.	2002 Feb	11889391
Mechanism of vascular relaxation by cholinomimetic drugs with special reference to pilocarpine and arecoline.	2002 Feb	11858612
Increased nasal mucosal swelling in subjects with asthma.	2002 Jan	12002739
Acute exudative inflammation and nasally exhaled nitric oxide are two independent phenomena.	2002 Jan-Feb	11891394
Segmental analysis of nasal cavity compliance by acoustic rhinometry.	2002 Jul	12070218
Naphazoline-induced neuroendocrine changes: increases in ANP and cGMP levels, but suppression of NE, 3H-NE, and cAMP levels in rabbit eyes.	2002 Jul	12037379
[The relationship between ostial patency and medical treatment in acute maxillary sinusitis: an experimental study].	2002 Jul-Aug	12422083
Intracellular sodium modulates the state of protein kinase C phosphorylation of rat proximal tubule Na+,K+-ATPase.	2002 Jun	12028137
Effects of oxymetazoline on the ventilation of paranasal sinuses in healthy subjects.	2002 Mar-Apr	12030359
Desensitization of alpha(2)-adrenoceptors which regulate noradrenaline synthesis and release after chronic treatment with clorgyline in the rat brain.	2002 May	11901301
Topical nasal anesthesia for transnasal fiberoptic laryngoscopy: a prospective, double-blind, cross-over study.	2003 Apr	12707645
Alpha(2A)-adrenergic versus imidazoline receptor controversy in rilmenidine's action: alpha(2A)-antagonism in humans versus alpha(2A)-agonism in rabbits.	2003 Dec	15028600
Effects of acute, repeated and chronic variable stress on in vivo tyrosine hydroxylase activity and on alpha(2)-adrenoceptor sensitivity in the rat brain.	2003 Dec	14660060
Functional characterisation of alpha(1)-adrenoceptors in denervated rat vas deferens.	2003 Jul	12845422
Central serous chorioretinopathy associated with administration of sympathomimetic agents.	2003 Jul	12834690
Alpha 2 adrenoceptor-mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons.	2003 Mar	12606912
[The use of oxymetazoline in nasal endoscopic sinus surgery].	2003 May	12916356
[Acute exposure to imidazoline derivatives in children].	2003 Nov-Dec	14685449
[Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis].	2003 Oct	14523532
Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization.	2003 Oct 10	12888550
Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.	2003 Sep	14579657
Alpha 2-adrenoceptors in the basal ganglia have a role in memory consolidation and reinforcement.	2003 Sep	12871653
Sympathomimetic drug allergy: cross-reactivity study by patch test.	2004	15554736
Bulk is a determinant of oxymetazoline affinity for the alpha1A-adrenergic receptor.	2004	15512845
[Ethyl-3H]RS-79948-197 alpha2-adrenoceptor autoradiography validation in alpha2-adrenoceptor knockout mice.	2004 Aug 30	15336948
Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions.	2004 Jan	14726922
Human alpha1D-adrenoceptor phosphorylation and desensitization.	2004 May 15	15130762
The Janus faces of adrenoceptors: factors controlling the coupling of adrenoceptors to multiple signal transduction pathways.	2004 Nov	15566401
Controlling bleeding from superficial wounds by the use of topical alpha adrenoreceptor agonists spray. A randomized, masked, controlled study.	2004 Nov	15488498
Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands.	2004 Oct	15451775
Thunderclap headache and reversible segmental cerebral vasoconstriction associated with use of oxymetazoline nasal spray.	2004 Sep 14	15367461
Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: an experimental study.	2005 Apr	15806055
Characterisation of alpha2-adrenoceptor subtypes involved in gastric emptying, gastric motility and gastric mucosal defence.	2005 Dec 28	16313902
Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction.	2005 Feb	15689767
Early changes in insulin secretion and action induced by high-fat diet are related to a decreased sympathetic tone.	2005 Jan	15353406
An assessment for the presence of bacterial contamination of Venturi principle atomizers in a clinical setting.	2005 Jan-Feb	15794070
Is oxymetazoline really safe for middle ear use.	2005 Jul	15995530
Otic barotrauma from air travel.	2005 May	15949100
[Investigation of the effect of oxymetazoline on the duration of rhinitis].	2005 Oct 13	16270513
[Investigation of the effect of oxymetazoline on the duration of rhinitis. results of a placebo-controlled double-blind study in patients with acute rhinitis].	2005 Oct 6	16261947
[The observation of the ciliotoxicity of nasal mucosa with nasal decongestant].	2005 Sep	16375111
Pharmacological characterization of postjunctional alpha-adrenoceptors in human nasal mucosa.	2005 Sep-Oct	16270605
Oxymetazoline inhibits proinflammatory reactions: effect on arachidonic acid-derived metabolites.	2006 Feb	16221739
In situ gelling, bioadhesive nasal inserts for extended drug delivery: in vitro characterization of a new nasal dosage form.	2006 Jan	16213127
Human breast cell lines exhibit functional alpha2-adrenoceptors.	2006 Jul	16292538
Simultaneous determination of triamcinolone acetonide and oxymetazoline hydrochloride in nasal spray formulations by HPLC.	2006 Mar 18	16297589

Patents

Sample Use Guides

In Vivo Use Guide

Pediatric Patients Nasal Congestion Intranasal For self-medication in children ≥6 years of age: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily. Conjunctival Congestion Ophthalmic For self-medication in children ≥6 years of age: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed. Adults Nasal Congestion Intranasal For self-medication: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily. Conjunctival Congestion Ophthalmic For self-medication: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.

Route of Administration: Nasal

In Vitro Use Guide

Oxymetazoline had a concentration-dependent inhibitory effect on cultured human nasal CBF from 0.25 to 2.00 g/L.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 22:15:32 UTC 2023` Edited by `admin` on `Thu Jul 06 22:15:32 UTC 2023`
Record UNII	8VLN5B44ZY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXYMETAZOLINE

Official Name

English

NASACON

Brand Name

English

AFRIN

Brand Name

English

OPERIL

Brand Name

English

OXYMETAZOLINE [VANDF]

Common Name

English

Oxymetazoline [WHO-DD]

Common Name

English

oxymetazoline [INN]

Common Name

English

PHENOL, 3-((4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL)-6-(1,1-DIMETHYLETHYL)-2,4-DIMETHYL-

Systematic Name

English

OXYMETAZOLINE [HSDB]

Common Name

English

6-TERT-BUTYL-3-(2-IMIDAZOLIN-2-YLMETHYL)-2,4-DIMETHYLPHENOL

Systematic Name

English

OXYMETAZOLINE [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QR01AA05